Cat.No. | Name | Information |
---|---|---|
M1658 | Axitinib | Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit. |
M2194 | SU5402 | SU5402 is a potent and selective VEGFR and FGFR inhibitor with IC50 values of 0.02, 0.03, 0.51 and > 100 μM for VEGFR2, FGFR1, PDGFRβ and EGFR respectively. |
M1838 | Masitinib | Masitinib is a tyrosine kinase inhibitor targeting stem cell factor receptor (c-kit) and platelet-derived growth factor (PDGF) receptor. |
M1956 | Apatinib mesylate | Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor of VEGFR2 with an IC50 of 2.43 nM. |
M1841 | Lenvatinib | Lenvatinib (E7080) is a potent inhibitor of multiple tyrosine kinases, including VEGF-R3 tyrosine kinase (IC50=5.2 nM) and VEGF-R2 tyrosine kinase (IC50=4.0 nM). |
M1669 | Regorafenib | Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively. |
M1827 | Sorafenib Tosylate | Sorafenib (BAY 43-9006) Tosylate is an orally active multikinase inhibitor of tyrosine protein kinases VEGFR/PDGFR and RAF/MEK/ERK with IC50 values of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. |
M1964 | Vandetanib | Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase (IC50=40 nM). Vandetanib also inhibited VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM). |
M5005 | Regorafenib Monohydrate | Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. |
M1882 | Vatalanib dihydrochloride | Vatalanib is a selective small molecule protein kinase inhibitor of VEGF receptors 1-3. |
M43549 | VEGFR-2-IN-32 | VEGFR-2-IN-32 is an inhibitor of VEGFR-2 with an IC50 of 8.93 nM. |
M43548 | VEGFR2-IN-4 | VEGFR2-IN-4 is a potent and selective VEGFR2 kinase inhibitor, with a GI50 of 0.7 nM. |
M43547 | VEGFR-2-IN-31 | VEGFR-2-IN-31 is a potent VEGFR-2 inhibitor (IC50=8.93 nM), and an anti-prostate cancer agent. |
M43546 | Bevasiranib | Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). |
M43545 | Bevasiranib sodium | Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). |
M43544 | hCA/VEGFR-2-IN-4 | hCA/VEGFR-2-IN-4 is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. |
M43543 | hCA/VEGFR-2-IN-3 | hCA/VEGFR-2-IN-3 is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. |
M43542 | hCA/VEGFR-2-IN-2 | hCA/VEGFR-2-IN-2 is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. |
M43541 | Arginyl-Glutamine | Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy. |
M43540 | Multi-kinase-IN-4 | Multi-kinase-IN-4 is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC50 values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. |
M43538 | TIE-2/VEGFR-2 kinase-IN-5 | TIE-2/VEGFR-2 kinase-IN-5 is an anti-angiogenic agent. |
M43537 | TIE-2/VEGFR-2 kinase-IN-4 | TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 5.2 nM and 5.1 nM, respectively. |
M43536 | TIE-2/VEGFR-2 kinase-IN-3 | TIE-2/VEGFR-2 kinase-IN-3, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 6.9 nM and 3.5 nM, respectively. |
M40945 | Pegaptanib Sodium | Pegaptanib Sodium is an RNA aptamer targeting vascular endothelial growth factor (VEGF)-165, a molecule of oligonucleotides chemically linked to polyethylene glycol (PEG), which can be used in studies related to neovascular age-related macular degeneration (AMD). |
M40602 | Alacizumab | Alacizumab is a monoclonal antibody against VEGFR2 that can be used in cancer-related studies. |
M40593 | Brolucizumab | Brolucizumab is a humanized single-chain anti-VEGF-A variable antibody fragment (scFv) that can be used in studies related to macular degeneration. |
M39851 | Jolkinolide A | Jolkinolide A is a diterpenoid, which exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of VEGF in A549 cells. |
M39845 | N-(p-Coumaroyl) Serotonin | N-(p-Coumaroyl) Serotonin inhibits PDGF-induced on phosphorylation of PDGF receptor and Ca2+ release from sarcoplasmic reticulum. N-(p-Coumaroyl) Serotonin ameliorates atherosclerosis and distensibility of the aortic wall in vivo and is usually used for the atherosclerosis research. |
M31300 | Faricimab | Faricimab is a bispecific antibody targeting Ang II and VEGF-A for studies related to eye disease and cardiovascular disease. |
M31082 | VEGFR-2-IN-5 hydrochloride | VEGFR-2-IN-5 hydrochloride is a VEGFR2 inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.